A μ-opioid receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Naloxonazine (hydrochloride)

Item No. 21950

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(5α)-[(5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazone, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-morphinan-6-one, dihydrochloride
CAS Number
880759-65-9
Synonyms
  • NLXZ
Molecular Formula
C38H42N4O6 • 2HCl
Formula Weight
723.7
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): Slightly soluble
SMILES
O[C@]12[C@]3(CCN(CC=C)[C@@H]2C4)[C@](OC5=C3C4=CC=C5O)([H])/C(CC1)=N/N=C(CC[C@@]6(O)[C@H]7CC8=CC=C9O)/[C@@]%10([H])[C@]6(CCN7CC=C)C8=C9O%10.Cl.Cl
InChi Code
InChI=1S/C38H42N4O6.2ClH/c1-3-15-41-17-13-35-29-21-5-7-25(43)31(29)47-33(35)23(9-11-37(35,45)27(41)19-21)39-40-24-10-12-38(46)28-20-22-6-8-26(44)32-30(22)36(38,34(24)48-32)14-18-42(28)16-4-2;;/h3-8,27-28,33-34,43-46H,1-2,9-20H2;2*1H/b39-23+,40-24+;;/t27-,28-,33+,34+,35+,36+,37-,38-;;/m1../s1
InChi Key
VIAIHLLKDJKEKM-DCBBKWFGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $81

    Add

    25 mg

    $181

    Add

    50 mg

    $341

    Add
    Product Description

    Naloxonazine is a μ-opioid receptor antagonist (Ki = 0.054 nM in a radioligand binding assay).1 It is selective for μ-opioid over κ- and δ-opioid receptors (Kis = 11 and 8.6 nM, respectively, in radioligand binding assays) and selectively binds to high-affinity µ1-opioid over μ- and δ-opioid receptors (Kds = 0.1, 2, and 5 nM, respectively).1,2 Naloxonazine (0.16 mg/kg) reverses sufentanil-induced antinociception, as well as hypercapnia and hypoxia, markers of respiratory depression, in rats.3 It reduces ethanol self-administration and food intake in rats when administered at a dose of 10 mg/kg.4 Naloxonazine (20 mg/kg) inhibits cocaine-induced place preference in rats.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Raynor, K., Kong, H., Chen, Y., et al. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharm. 45(2), 330-334 (1994).

    2. Cruciani, R.A., Lutz, R.A., Munson, P.J., et al. Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes. J. Pharmacol. Exp. Ther. 242(1), 15-20 (1987).

    3. Verborgh, C., and Meert, T.F. Antagonistic effects of naloxone and naloxonazine on sufentanil-induced antinociception and respiratory depression in rats. Pain 83(1), 17-24 (1999).

    4. Mhatre, M., and Holloway, F. μ1-opioid antagonist naloxonazine alters ethanol discrimination and consumption. Alcohol 29(2), 109-116 (2003).

    5. Rademacher, D.J., and Steinpreis, R.E. Effects of the selective μ1-opioid receptor antagonist, naloxonazine, on cocaine-induced conditioned place preference and locomotor behavior in rats. Neurosci. Lett. 332(3), 159-162 (2002).